Particle.news
Download on the App Store
3 ARTICLES
·
3d ago

Sobi to Acquire Arthrosi in Up to $1.5 Billion Deal to Bolster Gout Portfolio

The debt-funded purchase adds late-stage URAT1 inhibitor pozdeutinurad with 2026 Phase 3 results expected to guide filings.

Sobi will finance the upfront payment primarily via debt, utilising existing credit facilities and a new credit facility. Credit: © Swedish Orphan Biovitrum AB.

Overview

  • Sobi agreed to buy Arthrosi for as much as $1.5 billion, including $950 million in cash at closing and up to $550 million tied to clinical, regulatory and sales milestones.
  • The upfront payment will be financed primarily with debt through existing lines and a new credit facility from Handelsbanken and Danske Bank.
  • Pozdeutinurad (AR882) is a once-daily oral URAT1 inhibitor in two fully recruited global Phase 3 studies evaluating progressive and tophaceous gout, with readouts expected in 2026.
  • The transaction is subject to customary closing conditions and is expected to complete in the first half of 2026.
  • Viva Biotech expects an approximate $40 million gain and will continue supplying API via its Langhua unit, while ApicHope holds Greater China rights; Barclays advises Sobi and McDermott, Will & Schulte serves as legal counsel.